Müller, Thomas <br/><br/>
Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease.  [electronic resource] 

 -  Journal of neural transmission (Vienna, Austria : 1996)  May 2013 
 - 761-5 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1435-1463 
<br/><br/><label>Standard No.: </label>10.1007/s00702-012-0927-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Amphetamine--blood<br/>Antiparkinson Agents--therapeutic use<br/>Drug Substitution--methods<br/>Female<br/>Humans<br/>Indans--therapeutic use<br/>Male<br/>Methamphetamine--blood<br/>Middle Aged<br/>Motor Activity--drug effects<br/>Neuroprotective Agents<br/>Parkinson Disease--blood<br/>Selegiline--therapeutic use<br/>Severity of Illness Index<br/>Time Factors